PDF(Pubmed)
Abstract：
To analyze and compare the clinicopathological characteristics of male breast cancer (MBC) among Chinese patients and those from East Asia and other regions. Clinicopathological data from 3 kinds of data sources, including 31 MBC patients in Jiangsu Provincial Hospital (JPH) from 2014 to 2021 in China, 20 literature data on East Asian MBC patients from 2014 to 2021, and 3102 MBC patients registered in the surveillance, epidemiology, and end results (SEER) database from 2014 to 2019, were collected and retrospectively analyzed. The average ages of first-diagnosis MBC patients in JPH and East Asian patients were 59.7 and 62.3 years old, respectively, which were younger than those of SEER patients (66.5 years old). Between East Asian and SEER patients, the status or rates of main breast cancer type, estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2, breast subtype, and TNM stage were relatively close, and their differences were not statistically significant (P > .05). Differences were observed in chemotherapy, surgery, pathological grade, and lymph node positivity (P < .01). Furthermore, no statistically significant difference was observed between the JPH and East Asian patients (all P > .05). In JPH and SEER, linear regression relationships were observed between the lymph node positivity rate, tumor size, and histological grade. JPH and East Asian MBC patients were younger than SEER patients. Between East Asian and SEER patients, the status of the main breast cancer type, estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2, breast subtype, and TNM stage were similar, but there were differences in chemotherapy, surgery, pathological grade, and lymph node positivity. The findings of this study should prove to be helpful to deepen our understanding of East Asian MBC.
摘要：
分析比较中国人与东亚等地区男性乳腺癌的临床病理特征。临床病理数据来自3种数据源，包括2014年至2021年中国江苏省人民医院（JPH）的31例MBC患者，2014年至2021年东亚MBC患者的20篇文献数据，监测中登记的3102例MBC患者，流行病学,收集并回顾性分析2014年至2019年的最终结果（SEER）数据库。JPH和东亚患者中首次诊断为MBC患者的平均年龄分别为59.7和62.3岁，分别,比SEER患者（66.5岁）年轻。在东亚和SEER患者之间，主要乳腺癌类型的状态或发病率，雌激素受体，孕激素受体,人表皮生长因子受体2,乳腺亚型,和TNM阶段相对接近，差异无统计学意义(P>.05)。在化疗中观察到差异，手术,病理分级,淋巴结阳性（P<0.01）。此外，JPH患者与东亚患者之间无统计学差异（均P>0.05）。在JPH和SEER,观察淋巴结阳性率之间的线性回归关系，肿瘤大小,和组织学分级。JPH和东亚MBC患者比SEER患者年轻。在东亚和SEER患者之间，主要乳腺癌类型的状态，雌激素受体，孕激素受体,人表皮生长因子受体2,乳腺亚型,和TNM分期相似，但是化疗有差异，手术,病理分级,淋巴结阳性.这项研究的结果应该被证明有助于加深我们对东亚MBC的理解。
